Building native IgG-like bispecific antibodies that enhance drug-like properties
Build native IgG-like bispecific antibodies
Phanes’ bispecific antibody technology platform is PACbody®(PAC = Pairing of Alternative Cysteines), a proprietary approach for constructing bispecific antibodies that have native IgG-like structures with superb CMC characteristics. PACbodies can be designed to be fit for platform in the conventional manufacturing process for monoclonal antibodies.
PACbody® is a native IgG-like bispecific antibody platform with minimal structural change.
Build bispecific antibodies with enhanced manufacturability
Phanes’ second technology platform is SPECpair® (Shifted Properties Elicited by Charge pairs), which enables conventional fit-for-platform manufacturing process for native IgG-like bispecific antibodies.
Build bispecific antibodies with modulated activities
Phanes' third technology platform is ATACCbody® (Albumin-modulated Targeting of Antibodies to Cancer Cells), which allows for construction of conjugated IgG-like bispecific antibodies (ATACCbodies) whose activities are modulated by the environment they are in. The technology is designed for targeting solid tumors using immuno-oncology molecules with minimal risk of cytokine release syndrome (CRS) seen in traditional immuno-oncology therapies.